GlaxoSmithKline Makes Milestone Payment to Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc.In November 2011 MBBP client Alnylam Pharmaceuticals, Inc. entered into a partnership with pharmaceutical giant GlaxoSmithKline plc. (GSK) relating to  use of its RNA interference technology to enhance GSK’s vaccine products. On July 30th the partnership paid off, as Alnylam received a $3.2 million milestone payment from GSK with a possibility of future payments on unit product sales if its VaxiRNA technology is successfully applied in the manufacturing of a commercial vaccine.

Congratulations Alnylam Pharmaceuticals!

To learn more, please see the full article in the Boston Business Journal.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s